Carboplatin-based systemic therapy appeared associated with longer survival than cetuximab among patients with head and neck squamous cell carcinoma ineligible for cisplatin, according to study results.
We’re sorry, but an unexpected error has occurred.
Please refresh your browser and try again. If this error persists, please contact ITSupport@wyanokegroup.com for assistance.
Would you like to receive email reminders to complete your saved activities from Healio CME?
Activity saved! You'll receive reminders to complete your saved activities from Healio CME.
